In April 2018, SynAct Pharma AB (”SynAct Pharma”) implemented a rights issue of shares, in which the public was also given the opportunity to subscribe for shares. Through the rights issue , 2,257,718 shares were issued. The last day of trading in BTA (Betald Tecknad Aktie) (aid subscribed shares) is 4th June 2018 and the stop date is 7th June 2018.
2,257,718 shares have been registered with the Swedish Companies registration office and these are expected to be distributed to the respective VP account/depository on 11th June 2018. After registration with the Swedish Companies Registration Office, the total number of shares in SynAct Pharma amounts to 14,675,167.
Financial advisor
Sedermera Fondkommission is the financial advisor to SynAct Pharma in connection with the rights issue.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Henrik Stage
CEO, SynAct Pharma AB CFO, SynAct Pharma AB
Telephone: +45 28 44 75 67 Telephone: +45 40 26 09 00
E-mail: [email protected] E-mail: hs@synactpharma.com